Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PCRX | DEFA14A | mixed | 6/10 | Pacira BioSciences issued a press release defending its intellectual property strategy against activist investor DOMA Pe | May 26, 2026 |
| SER | CLUSTER | bearish | 5/10 | Two Serina directors made small open-market purchases totaling ~$38K in the 7-day window ending May 22, 2026. These trad | May 26, 2026 |
| IVEVF | 6-K | neutral | 4/10 | Inventiva reported Q1 2026 cash of €75.0M and short-term deposits of €121.5M, down from €99.3M and €131.6M respectively | May 26, 2026 |
| KPTI | CLUSTER | neutral | 3/10 | Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the s | May 26, 2026 |
| ICLR | 6-K | bearish | 6/10 | ICON plc disclosed receipt of a Nasdaq deficiency notice due to the delayed filing of its Form 20-F for FY2025, and anno | May 26, 2026 |
| JBIO | PRESS-RELEASE | neutral | 3/10 | Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE201, a half-life exte | May 26, 2026 |
| VRDN | 8-K | neutral | 4/10 | Viridian Therapeutics entered into a commercial manufacturing services agreement with WuXi Biologics for long-term suppl | May 26, 2026 |
| KPTI | CLUSTER | neutral | 2/10 | Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000 | May 26, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Six TWST insiders, including the CEO, CFO, and COO, collectively sold 16,796 shares for ~$807K on May 21, 2026, all at $ | May 26, 2026 |
| SNTI | 8-K | bearish | 7/10 | Senti Biosciences issued $10.0M in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SP | May 26, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from | May 26, 2026 |
| APGE | PRESS-RELEASE | neutral | 6/10 | Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, | May 26, 2026 |
| BPTH | 8-K | bearish | 7/10 | Bio-Path is abandoning its pharmaceutical focus to launch a Digital Asset Treasury 2.0 (DAT 2.0) using AI for crypto tra | May 26, 2026 |
| XOMAP | 425 | bullish | 7/10 | XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection with the proposed a | May 26, 2026 |
| TCRT | 8-K | bearish | 6/10 | Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral non-hormonal obesity candidate, sh | May 26, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK filed a 6-K reporting the admission of 45,273 ordinary shares to trading on the London Stock Exchange under its exis | May 26, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK plc disclosed routine weekly share repurchases under its existing buyback program, buying 1.67 million shares betwee | May 26, 2026 |
| GANX | 8-K | bullish | 5/10 | Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkins | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 8/10 | Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~ | May 26, 2026 |
| AWHL | 8-K | neutral | 4/10 | Aspira Women's Health entered a Master Collaboration and License Agreement with Cleveland Clinic to jointly develop AI-p | May 26, 2026 |
| GOVX | S-1 | neutral | 3/10 | GeoVax Labs filed an S-1 registration statement to register up to 7.64 million shares of common stock for resale by inst | May 26, 2026 |
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics filed its management information circular and notice of annual general meeting for June 24, 2026. T | May 26, 2026 |
| CRBP | 8-K | bullish | 7/10 | Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9% confirmed ORR in 2L | May 26, 2026 |
| SLXNW | 8-K | neutral | 5/10 | Silexion Therapeutics announced a 1-for-10 reverse share split, effective after market close on May 28, 2026, with split | May 26, 2026 |
| PRFX | 6-K | neutral | 4/10 | PRF Technologies (PRFX) announced positive preclinical results for its lead candidate PRF-110, showing sustained 72-hour | May 26, 2026 |
| PRFX | PRESS-RELEASE | bullish | 5/10 | PRF Technologies announced positive preclinical head-to-head results for PRF-110 vs. ZYNRELEF in a pig incisional pain m | May 26, 2026 |
| RNXT | PRESS-RELEASE | bullish | 5/10 | RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that in | May 26, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics announced a 1-for-10 reverse share split effective May 28, 2026, to regain compliance with Nasdaq' | May 26, 2026 |
| COCP | 8-K | bullish | 6/10 | Cocrystal Pharma announced the discovery of novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza, | May 26, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced that the Johns Hopkins IRB approved advancing its Phase I/II CMND-100 trial to Parts B and | May 26, 2026 |